Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …

To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …